April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Phase 1, Dose-Escalating Study of the Safety, Tolerability, and Pharmacokinetics of ACU-4429 in Healthy Volunteers
Author Affiliations & Notes
  • R. Kubota
    Acucela Inc, Bothell, Washington
  • D. Birch
    Retina Foundation of the Southwest, Dallas, Texas
  • R. David
    Acucela Inc, Bothell, Washington
  • Footnotes
    Commercial Relationships  R. Kubota, Acucela Inc., E; D. Birch, Retina Foundation of the Southwest, F; Retina Foundation of the Southwest, C; Retina Foundation of the Southwest, R; R. David, Acucela Inc., C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5009. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Kubota, D. Birch, R. David; Phase 1, Dose-Escalating Study of the Safety, Tolerability, and Pharmacokinetics of ACU-4429 in Healthy Volunteers. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5009.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : This study assessed the safety, tolerability, and pharmacokinetics (PK) of single-dose oral administration of ACU-4429, a novel non-retinoid visual cycle modulator, in healthy volunteers aged 55-80 years. Additionally, electroretinographic (ERG) measurements were performed to assess the effect of ACU-4429 on rod-mediated retinal activity.

Methods: : This was a single-center, randomized, double-masked, placebo-controlled, dose-escalation study. Three cohorts of 6 subjects each (5 ACU-4429, 1 placebo) received a single oral dose of placebo or ACU-4429, starting at 2 mg (approximately 0.03 mg/kg for a 70-kg individual). The study involved 5 visits: screening (up to 35 days before Day -1); baseline (Day -1, predose); treatment and inpatient period (Day 1 dosing and Day 2 inpatient follow-up); outpatient follow-up (Day 3); and study exit (Days 6-7). Full-field ERGs were recorded following dark adaptation and at 10-minute intervals after exposure to a bleaching light.

Results: : Oral administration of ACU-4429 was well tolerated up to 20mg. No significant or unexpected adverse events were reported. One case of mild and transient alteration in dark adaptation was reported in the 20mg cohort. Plasma concentrations were generally below the level of assay for the 2mg cohort. For the higher cohorts, AUC and Cmax increased approximately proportional to dose. Cmax was 1.42ng/mL and 4.54ng/mL in the 7mg and 20mg cohorts, respectively; median Tmax is 4-6 hours postdose. Mean T1/2 is 4 hours for the 7mg cohort and 6 hours for the 20mg cohort. Mean residence time was approximately 8-10 hours postdose. Dark-adapted ERGs were not affected. However, most subjects demonstrated a marked slowing of the time course of recovery following the bleach for 24 to 48 hours postdose. The slowing persisted on Day 2, but was not seen at the exit visit.

Conclusions: : ACU-4429 is safe and well tolerated when taken orally by healthy volunteers aged 55-80 years. PK data indicate ACU-4429 has a half life of approximately 4-6 hours. The prolonged course of ERG dark adaptation seen in most subjects indicates ACU-4429 may effectively slow the rod visual cycle.

Clinical Trial: : www.clinicaltrials.gov NCT00703183

Keywords: age-related macular degeneration • retina • degenerations/dystrophies 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.